Optimal First-line Eradication Regimens for Helicobacter pylori Infection in Patients with Clarithromycin Resistance: A Pilot Study
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
; : 242-246, 2018.
Article
em Ko
| WPRIM
| ID: wpr-738982
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND/AIMS: Helicobacter pylori eradication rates using first-line treatment have decreased due to clarithromycin resistance. The aim of this study was to investigate optimal eradication regimens for patients with clarithromycin resistance in Korea. MATERIALS AND METHODS: A total of 72 patients with confirmed clarithromycin resistance were enrolled from August 2015 to July 2017. Patients were randomized to a 7-day bismuth quadruple therapy (BQT) regimen or a 7-day metronidazole triple therapy (MTT) regimen. Eradication was confirmed using the 13C-urea breath test. RESULTS: There were no differences in baseline characteristics between the groups. Intention-to-treat eradication rates were 77.8% for the BQT group and 66.7% for the MTT group (P=0.293). Per protocol eradication rates were 87.5% for the BQT group and 77.4% for the MTT group (P=0.292). Adverse events were more frequent in the BQT group. CONCLUSIONS: Eradication rates using MTT were comparable to those using BQT, and adverse events were less frequent in the MTT group. Thus, MTT may be considered as a first-line regimen for patients with clarithromycin resistance. Since this was a pilot study, a study with a large group is required.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Bismuto
/
Testes Respiratórios
/
Projetos Piloto
/
Helicobacter pylori
/
Helicobacter
/
Claritromicina
/
Coreia (Geográfico)
/
Metronidazol
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Humans
País/Região como assunto:
Asia
Idioma:
Ko
Revista:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Ano de publicação:
2018
Tipo de documento:
Article